Skip to main content

Table 1 Patient and tumour characteristics of the study population

From: Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial

 All patients, n = 106Patients with low TILs, n = 81Patients with intermediate TILs, n = 25 
Characteristicn% (col)n% (col)n% (col)p1
Age (years)0.12
 60–6944(41)44(54)18(72) 
 70–8962(59)37(46)7(28) 
Tumour size (mm)20.32
 <  2046(43)33(41)13(52) 
 ≥ 2060(57)48(59)12(48) 
Histological subtype0.40
 Ductal76(72)56(70)19(76) 
 Lobular12(11)11(14)1(4) 
 Other invasive317(16)13(16)5(20) 
 Unknown1(1)1(1)0  
Malignancy grade40.96
 137(43)28(42)9(45) 
 245(52)35(52)10(50) 
 35(6)4(6)1(5) 
Axillary node status0.08
 Negative58(55)41(51)17(68) 
 Positive47(44)40(49)7(28) 
 Unknown1(1)0 1(4) 
Oestrogen receptor status (%)0.18
 10–9920(19)13(16)7(28) 
 10086(81)68(84)18(72) 
Progesterone receptor status (%)0.20
 10–9975(71)57(70)18(72) 
 10029(27)22(27)7(28) 
 Unknown2(2)2(3)0(0) 
Ki67 index (%)0.02
 < 1472(68)60(74)12(48) 
 ≥ 1432(30)20(25)12(48) 
 Unknown2(2)1(1)1(4) 
  1. 1Excluding unknowns; 2range 11–100 mm; 3other invasive: mucinous carcinomas n = 8, tubular carcinomas n = 2, medullary carcinoma n = 1, not specified n = 6; 4only lobular and ductal tumours graded, n = 88
  2. TILs, tumour-infiltrating lymphocytes